Fig. 2

CXCL11 was highly expressed in NSCLC patients with DOC-based chemotherapy, and promoted the accumulation of CD8⁺ T cells. a Expression levels of chemokine expression in tumor tissue (T) and adjacent normal tissues (N). Chemokine gene expression was validated in tumor tissues (T) and adjacent normal tissues (N) using qRT-PCR analysis. Statistical differences between groups were determined by the Mann-Whitney rank-sum test (n = 77). *P < 0.05; NS, non-significant (P > 0.05). b Expression of CXCL11 mRNA in lung cancer tumor tissues and adjacent tissue, as detected by qRT-PCR. Samples with CXCL11 in higher in tumor tissue than adjacent tissue are highlighted in red. c, d The comparative expression of CXCL11 and CD8 in non DOC combined with L-OHP group (n = 72) and DOC combined with L-OHP group (n = 5). Data are given as means ± SEM. Significance is noted as **p < 0.0001. e, f Immunofluorescence staining using anti-CD8 mAbs in sections from untreated (without DOC+L-OHP treatment) group and chemotherapy (DOC combined with L-OHP) group patients, and the differences were significant (n = 5). Scale bars, 50 μm. g, h Immunohistochemistry staining of CD8 in sections from patient samples before chemotherapy and after chemotherapy (DOC combined with L-OHP), and the differences were significant (n = 9). Scale bars, 100 μm. i, j Immunofluorescence staining of CD8 (green), CXCR3 (red) and DAPI (blue) in lung tumor tissue (n = 5). Scale bars, 50 μm